



07-14-06

<b>Office Action Summary</b>	<b>Application No.</b>	<b>Applicant(s)</b>
	10/619,709	NGUYEN ET AL.
	Examiner Melissa Perreira	Art Unit 1618

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

#### Status

- 1) Responsive to communication(s) filed on 14 July 2003.
- 2a) This action is FINAL.      2b) This action is non-final.
- 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

#### Disposition of Claims

- 4) Claim(s) 1-53 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.
- 5) Claim(s) \_\_\_\_\_ is/are allowed.
- 6) Claim(s) \_\_\_\_\_ is/are rejected.
- 7) Claim(s) \_\_\_\_\_ is/are objected to.
- 8) Claim(s) 1-53 are subject to restriction and/or election requirement.

#### Application Papers

- 9) The specification is objected to by the Examiner.
- 10) The drawing(s) filed on \_\_\_\_\_ is/are: a) accepted or b) objected to by the Examiner.  
 Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  
 Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

#### Priority under 35 U.S.C. § 119

- 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) All    b) Some \* c) None of:
1. Certified copies of the priority documents have been received.
2. Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

#### Attachment(s)

- |  |   |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892)   | 4) <input type="checkbox"/> Interview Summary (PTO-413)                     |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948)                                   | Paper No(s)/Mail Date. _____  |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)<br>Paper No(s)/Mail Date _____ | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
|  | 6) <input type="checkbox"/> Other: _____                                    |

## REFERENCES

### US patent documents

5,559,038      September 24, 1996      J. Fred Kolhouse  
6,358,996      March 19, 2002      Michael S. Alexander

### Other references

Nieves Pizarro et al, "Determination of MDMA and its metabolites in blood and urine by GC-MS and analysis of enantiomers by capillary electrophoresis", Journal of Analytical Toxicology, April 2002, page 157-165, vol. 26.

Hideyuki Yamada et al, "Dansyl chloride derivatization of methamphetamine : a method with advantages for screening and analysis of methamphetamine in urine", Journal of Analytical Toxicology, Jan/Feb 2002, page 17-22, vol. 19.

Petr Husek and Petr Simek, "Advances in amino acid analysis", LCGC Sep 2001, page 986-999, vol.19.

Dong-Liang-Lin et al, "Chemical derivatization and the selection of deuterated internal standard for quantitative determination-methamphetamine example", Journal of Analytical Toxicology, May/June 2000, page 275-280, vol. 24.

Maciej Bogusz et al, "Analysis of underivatized amphetamines and related phenethylamines with HPLC-APCI-MS", Journal of Analytical Toxicology, March 2000 page 77-84, vol. 24.

Barbara A. Way et al, "Isotope dilution GC-MS measurement of tricyclic antidepressant drugs. Utility of the 4-carbethoxyhexafluorobutyryl derivatives of secondary amines", Journal of Analytical Toxicology, Sep 1998, page 374-382, vol. 22.

Maciej Bogusz, " Determination of phenylisothicyanate derivatives of amphetamine and its analogues in biological fluids by HPLC-APCI-MS or DAD", Journal of Analytical Toxicology, Jan/Feb 1997, page 59-69, vol. 21.

Kenji Hara et al, "Simple extractive derivatization of methamphetamine and its metabolites in biological materials with extrelut columns for their GC-MS determination", Journal of Analytical Toxicology, Jan/Feb 1997, page 54-58, vol. 21.

P. Dallakian et al, "Detection and quantitation of amphetamine and methamphetamine : EI and CI with ammonia – comparative investigation on Shimadzu QP5000 GC-MS system", Journal of Analytical Toxicology, July/Aug 1996, page 255-261, vol. 20.

Robert Meatherall, "Rapid GC-MS confirmation of urinary amphetamine and methamphetamine as their propylchloroformate derivatives", Journal of Analytical Toxicology, Sep 1995, page 316-322, vol. 19.



COPY OF ORIGINAL PATENT APPLICATION

**STATEMENT :**

This is the copy of the original patent application submitted on July 14,2003.